GlaxoSmithKline logo

GSK - GlaxoSmithKline Share Price

1346.4p -2.0  -0.1%

Last Trade - 16/04/21

Large Cap
Market Cap £67.84bn
Enterprise Value £94.84bn
Revenue £34.10bn
Position in Universe 24th / 1818
Unlock GSK Revenue
Relative Strength (%)
1m +1.54%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -22.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
23,923 27,889 30,186 30,821 33,754 34,099 33,786 35,535 +7.3%
-16.4 -40.1 +189.1 -9.8 +58.6 -28.2 +3.41 +11.4
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020,GlaxoSmithKline plc revenues increased 1% to £34.1B. Netincome increased 24% to £5.75B. Revenues reflect ConsumerHealthcare segment increase of 12% to £10.03B, US segmentincrease of 5% to £14.56B, UK segment increase of 4% to£980M. Net income benefited from Unallocated segment lossdecrease of 46% to £1.33B, Consumer Healthcare segmentincome increase of 18% to £2.21B.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for GSK
Graphical History


GSK Revenue Unlock GSK Revenue

Net Income

GSK Net Income Unlock GSK Revenue

Normalised EPS

GSK Normalised EPS Unlock GSK Revenue

PE Ratio Range

GSK PE Ratio Range Unlock GSK Revenue

Dividend Yield Range

GSK Dividend Yield Range Unlock GSK Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
GSK EPS Forecasts Unlock GSK Revenue
Profile Summary

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated December 6, 1999
Public Since May 22, 1972
No. of Shareholders: 103,528
No. of Employees: 94,066
GSK Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for GSK
Upcoming Events for GSK
Wednesday 28th April, 2021
Q1 2021 GlaxoSmithKline PLC Earnings Release
Wednesday 28th April, 2021
Q1 2021 GlaxoSmithKline PLC Earnings Call
Wednesday 5th May, 2021
GlaxoSmithKline PLC Annual Shareholders Meeting
Thursday 6th May, 2021 Estimate
GlaxoSmithKline PLC Annual Shareholders Meeting
Monday 7th June, 2021 Estimate
GlaxoSmithKline PLC Biopharma Investor Update
Wednesday 23rd June, 2021
GlaxoSmithKline PLC Biopharma Investor Update
Wednesday 28th July, 2021
Q2 2021 GlaxoSmithKline PLC Earnings Release
Frequently Asked Questions for GlaxoSmithKline
What is the GlaxoSmithKline share price?

As of 16/04/21, shares in GlaxoSmithKline are trading at 1346.4p, giving the company a market capitalisation of £67.84bn. This share price information is delayed by 15 minutes.

How has the GlaxoSmithKline share price performed this year?

Shares in GlaxoSmithKline are currently trading at 1346.4p and the price has moved by -14.11% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the GlaxoSmithKline price has moved by -32.8% over the past year.

What are the analyst and broker recommendations for GlaxoSmithKline?

Of the analysts with advisory recommendations for GlaxoSmithKline, there are there are currently 5 "buy" , 14 "hold" and 0 "sell" recommendations. The overall consensus recommendation for GlaxoSmithKline is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will GlaxoSmithKline next release its financial results?

GlaxoSmithKline is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the GlaxoSmithKline dividend yield?

The GlaxoSmithKline dividend yield is 5.93% based on the trailing twelve month period.

Does GlaxoSmithKline pay a dividend?

Last year, GlaxoSmithKline paid a total dividend of 0.8, and it currently has a trailing dividend yield of 5.93%. Looking ahead, GlaxoSmithKline has not announced an ex-dividend date yet.

When does GlaxoSmithKline next pay dividends?

GlaxoSmithKline has yet to annouce their ex-dividend date. The historic dividend yield on GlaxoSmithKline shares is currently 5.93%.

How do I buy GlaxoSmithKline shares?

To buy shares in GlaxoSmithKline you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of GlaxoSmithKline?

Shares in GlaxoSmithKline are currently trading at 1346.4p, giving the company a market capitalisation of £67.84bn.

Where are GlaxoSmithKline shares listed? Where are GlaxoSmithKline shares listed?

Here are the trading details for GlaxoSmithKline:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: GSK
What kind of share is GlaxoSmithKline?

Based on an overall assessment of its quality, value and momentum, GlaxoSmithKline is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a GlaxoSmithKline share price forecast 2021?

Shares in GlaxoSmithKline are currently priced at 1346.4p. At that level they are trading at 13.61% discount to the analyst consensus target price of 1,558.51.

Analysts covering GlaxoSmithKline currently have a consensus Earnings Per Share (EPS) forecast of 1.00677 for the next financial year.

How can I tell whether the GlaxoSmithKline share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like GlaxoSmithKline. Over the past six months, the relative strength of its shares against the market has been -20.12%. At the current price of 1346.4p, shares in GlaxoSmithKline are trading at -4.29% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the GlaxoSmithKline PE Ratio?

The GlaxoSmithKline PE ratio based on its reported earnings over the past 12 months is 13.85. The shares are currently trading at 1346.4p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of GlaxoSmithKline?

GlaxoSmithKline's management team is headed by:

Phil Thomson - CEX
Emma Walmsley - CEO
Roger Connor - CEX
Marvinder Banga - NID
Vivienne Cox - NID
Luke Miels - CEX
Brian McNamara - CEX
Regis Simard - CEX
Iain Mackay - CFO
James Ford - SVP
Jonathan Symonds - NEC
Diana Conrad - SVP
Deborah Waterhouse - CEX
Charles Bancroft - NID
Anne Beal - NID
Who are the major shareholders of GlaxoSmithKline?

Here are the top five shareholders of GlaxoSmithKline based on the size of their shareholding:

BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 6.6% (332.2m shares)
Dodge & Cox Investment Advisor/Hedge Fund
Percentage owned: 5.04% (253.5m shares)
Capital Research Global Investors Investment Advisor
Percentage owned: 3.98% (200.3m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 3.3% (166.2m shares)
Statens Pensjonsfond Utland Mutual Fund
Percentage owned: 2.48% (124.9m shares)
Similar to GSK
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.